Elicio Therapeutics, Inc. Common Stock (ELTX) is a publicly traded Healthcare sector company. As of May 21, 2026, ELTX trades at $9.97 with a market cap of $182.65M and a P/E ratio of -3.85. ELTX moved +8.18% today. Year to date, ELTX is +26.84%; over the trailing twelve months it is +81.27%. Its 52-week range spans $4.05 to $14.93. Analyst consensus is strong buy with an average price target of $18.00. Rallies surfaces ELTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Elicio to Present at May 14 Bank of America Conference; Lead ELI-002 Showed 16.3-Month RFS: Elicio Therapeutics will present at the Bank of America Healthcare Conference on May 14, 2026 at 12:20 PM ET with CEO Robert Connelly and three senior executives. Lead candidate ELI-002 7P targeting mKRAS-positive tumors achieved 16.3-month median recurrence-free survival and 28.9-month median overall survival in Phase 1.
| Metric | Value |
|---|---|
| Price | $9.97 |
| Market Cap | $182.65M |
| P/E Ratio | -3.85 |
| EPS | $-2.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.93 |
| 52-Week Low | $4.05 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-39.57M |
| Gross Margin | 0.00% |
4 analysts cover ELTX: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.00.